A Study of a Novel Precision Medicine Approach For Obesity

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT06814938
Phase
PHASE4
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    2.4 mg subcutaneous weekly
  • Placebo — DRUG
    Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly

Study Details

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

Key Dates

Start date
Feb 21, 2025
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Nov 30, 2028

Study Design

Enrollment
135 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide Group
    Subjects will take semaglutide weekly for 24 weeks
  • Placebo Comparator: Placebo Group
    Subjects will take placebo weekly for 24 weeks.

Primary Outcome Measure

Change in Total Body Weight at 24 weeks [ Time Frame: Baseline, 24 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic in FloridaJacksonvilleFlorida32224-
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Jacksonville, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Mayo Clinic in Florida· Jacksonville, FLMayo Clinic in Rochester· Rochester, MN

Related Studies